Citations available for content in Chicago, APA and MLA format.
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
U.S. Congress. House. Depression Side Effect Labeling Awareness Act of 2018. H.R. 6717. 115th Cong., 2nd sess., Introduced in House September 6, 2018. https://www.govinfo.gov/app/details/BILLS-115hr6717ih.
House of Representatives, Congress. (). H.R. 6717 (IH) - Depression Side Effect Labeling Awareness Act of 2018. [Government]. U.S. Government Publishing Office. https://www.govinfo.gov/app/details/BILLS-115hr6717ih
House of Representatives, Congress. H.R. 6717 (IH) - Depression Side Effect Labeling Awareness Act of 2018. U.S. Government Publishing Office, , https://www.govinfo.gov/app/details/BILLS-115hr6717ih
H.R.6717 - 115th Congress (2017-2018): Depression Side Effect Labeling Awareness Act of 2018, H.R.6717, 115th Cong. (2018), https://www.govinfo.gov/app/details/BILLS-115hr6717ih.
Close xBills and Statutes
Congressional Bills
Y 1.6:
Y 1.4/6:
115th Congress
2nd Session
September 6, 2018
Mr. Rush introduced the following bill; which was referred to the Committee on Energy and Commerce
H.R. 6717
Introduced in House (IH)
Depression Side Effect Labeling Awareness Act of 2018
To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.
Bobby L. Rush (IL)
Committee on Energy and Commerce (Standing)
21 U.S.C. 352